Stockreport

Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue

Eyenovia, Inc.  (EYEN) 
Last eyenovia, inc. earnings: 3/25 04:05 pm Check Earnings Report
PDF NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose arr [Read more]